Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 24 May 2024, including: Biogen, Inc.’s immunology acquisition; AstraZeneca PLC looks to cement respiratory lead; why the US FTC is tough on pharma; the US election’s impact on pharma; and how new AI tools are impacting medical affairs.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal" - Scrip, 22 May, 2024.)
(Also see "AstraZeneca Confident Of Cementing Lead In Respiratory" - Scrip, 17 May, 2024.)
(Also see "FTC Is Taking A Tougher Stance On Pharma; A Deputy Director Explains Why" - Scrip, 17 May, 2024.)
(Also see "The Looming US Election Weighs On The Minds Of Pharma" - Scrip, 20 May, 2024.)
(Also see "'We Are Not Waiting To Be Replaced': Medical Affairs Pros Take On GPT-4o" - Scrip, 21 May, 2024.)
